A representation of monoclonal antibodies binding to antigens on a cell surface.
Anna Tanczos/Wellcome Images
Before becoming a Covid-19 drug, each candidate was just a tiny fragment of someone’s immune system, part of a swarm of Y-shaped proteins unleashed to try to keep the coronavirus from invading more cells. If the person recovered, these antibodies might end up in a blood sample in a lab. Some proved more effective than others. Yet even as researchers pinpointed the best of the bunch as possible medications, they knew their power could wane: What worked against the coronavirus as it was last year could falter as the pathogen evolved.
Rheumatoid Arthritis Drug May Reduce COVID Death Risk webmd.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webmd.com Daily Mail and Mail on Sunday newspapers.